

ANTIFUNGALS, ORAL PRIOR AUTHORIZATION FORM

To review the prior authorization guidelines for Oral Antifungals, please refer to the Medical Assistance Prior Authorization of Pharmaceutical Services Handbook Chapters – **Antifungals, Oral** and **Quantity Limits/Daily Dose Limits** (accessible at: <http://www.dhs.pa.gov/provider/pharmacyservices/drugsrequiringclinicalpriorauthorization/index.htm>).

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	Total # of pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
LTC facility contact/phone:		NPI:	MA Provider ID#:
RECIPIENT INFORMATION		Street address:	
Recipient Name:		Suite #:	City/state/zip:
Recipient ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Non-preferred medication requested			
<input type="checkbox"/> Ancobon capsule	<input type="checkbox"/> griseofulvin microsize tablet	<input type="checkbox"/> Noxafil DR tablet	<input type="checkbox"/> Sporanox solution
<input type="checkbox"/> Cresemba capsule	<input type="checkbox"/> Gris-PEG tablet	<input type="checkbox"/> Noxafil suspension	<input type="checkbox"/> VFEND tablet
<input type="checkbox"/> Diflucan tablet	<input type="checkbox"/> itraconazole capsule	<input type="checkbox"/> Onmel tablet	<input type="checkbox"/> VFEND suspension
<input type="checkbox"/> Diflucan suspension	<input type="checkbox"/> ketoconazole tablet	<input type="checkbox"/> Oravig buccal tablet	<input type="checkbox"/> voriconazole tablet
<input type="checkbox"/> flucytosine capsule	<input type="checkbox"/> Lamisil tablet	<input type="checkbox"/> Sporanox capsule	<input type="checkbox"/> voriconazole suspension
Directions:		Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):		DX code (<i>required</i>):	
1. Has the Recipient tried and failed any of the preferred Oral Antifungals? <i>Check all that apply.</i>		<input type="checkbox"/> Yes – <i>Submit all supporting documentation of drug regimen and therapeutic failure.</i>	
<input type="checkbox"/> clotrimazole troche	<input type="checkbox"/> griseofulvin ultramicrosize tablet	<input type="checkbox"/> No	
<input type="checkbox"/> fluconazole tablet or suspension	<input type="checkbox"/> nystatin tablet or suspension		
<input type="checkbox"/> griseofulvin microsize suspension	<input type="checkbox"/> terbinafine tablet		
2. Does the Recipient have any contraindications or intolerances to any of the preferred agents listed in question (1)?		<input type="checkbox"/> Yes – <i>Submit all supporting documentation of medication name(s) and associated intolerances and contraindications.</i>	
		<input type="checkbox"/> No	
3. Does the Recipient have a diagnosis for which none of the preferred Oral Antifungals are indicated or widely medically-accepted? <i>Check all that apply or indicate diagnosis.</i>		<input type="checkbox"/> Yes – <i>Submit documentation of diagnosis and planned duration of treatment.</i>	
<input type="checkbox"/> aspergillosis	<input type="checkbox"/> mucormycosis	<input type="checkbox"/> No	
<input type="checkbox"/> blastomycosis	<input type="checkbox"/> other (specify): _____		
<input type="checkbox"/> histoplasmosis	_____		

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.